Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies.

ABSTRACT:

Background

It is well known that the gastrointestinal (GI) microbiota can influence the metabolism, pharmacokinetics, and toxicity of cancer therapies. Conversely, the effect of cancer treatments on the composition of the GI microbiota is poorly understood. We hypothesized that oral androgen receptor axis-targeted therapies (ATT), including bicalutamide, enzalutamide, and abiraterone acetate, may be associated with compositional differences in the GI microbiota.

Methods

We profiled the fecal microbiota in a cross-sectional study of 30 patients that included healthy male volunteers and men with different clinical states of prostate cancer (i.e., localized, biochemically recurrent, and metastatic disease) using 16S rDNA amplicon sequencing. Functional inference of identified t

SUBMITTER: Sfanos KS 

PROVIDER: S-EPMC6283851 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature